The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis

Launched by FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE · Mar 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called Shenfu Injection in patients with septic shock, a serious condition caused by severe infections that can harm the heart. The goal is to see if adding Shenfu Injection to the usual treatments can help prevent heart problems, speed up recovery if heart issues do occur, and ultimately improve survival rates for patients. Participants will be divided into two groups: one will receive standard treatment for septic shock, while the other will receive that same treatment along with Shenfu Injection.

To be eligible for this trial, patients must be at least 18 years old and diagnosed with septic shock. However, certain individuals, such as pregnant women, those with severe heart conditions, or patients with other serious health issues, cannot participate. If you or someone you know is considering joining this trial, they can expect to receive close monitoring and care from healthcare professionals as part of the study. This trial is currently recruiting participants and aims to make a significant difference in how septic shock is managed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients clinically diagnosed with septic shock must meet the diagnostic criteria of Sepsis 3.0;
• • 2. Age ≥ 18 years.
• Exclusion Criteria:
• • 1. Pregnant or breastfeeding women;
• • 2. Individuals with a history of allergies or known hypersensitivity to Ginseng and Aconite Injection or its components;
• • 3. Severe underlying diseases that may affect prognosis, including uncontrolled malignant tumors with multiple metastases that are unresectable, hematological disorders, cachexia, persistent active bleeding, severe malnutrition, HIV, etc.;
• • 4. Severe cardiac conditions within the last three months, including acute unstable myocardial infarction, dilated cardiomyopathy, acute coronary syndrome, acute or chronic valvular heart disease, and congestive heart failure (New York Heart Association \[NYHA\] Class IV);
• • 5. Any of the following medical procedures performed within the last three months: any form of cardiac surgery, thoracotomy, external cardiac compression, defibrillation, direct current cardioversion, or trauma;
• • 6. Use of Ginseng and Aconite Injection for less than 48 hours;
• • 7. Patients expected to die within 48 hours;
• • 8. Patients deemed unsuitable for this study by the investigator.